FDA has approved autologous T cells engineered to express a CAR targeting CD19 for the treatment of refractory pre-B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma (42). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.